Accessibility and reading comfort

Text size

Light/Dark mode

Lines vertical spacing

Trouble using our website?
Contact us

A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema (Meerkat)

In this page

Clinical Trial

NCT05642312 Recruiting, Active
A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema (Meerkat)

A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Investigate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Vamikibart Administered Intravitreally in Patients With Uveitic Macular Edema

Phase 3
Interventional

Disease

Disease type

Uveitis

Orphan drug recognition

Yes

Patient type

Adult

Children

Inclusion / Exclusion

Opening date

09/01/2023

Closing date

30/06/2025

Inclusion criteria :

More

Exclusion criteria :

More

Funding

private

Members involved

Others investigators

Pr Andreas Wedrich

Representative

Austria

See more

Prof Markus Ritter

Representative

Austria

Research (TWG8), Retinal Rare Eye Diseases (WG1)
See more

Dr Ingeborgh VAN DEN BORN

Representative

Netherlands

Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)
See more

Dr João Pedro Marques

Substitute

Portugal

National Integration (TWG9), Research (TWG8), Retinal Rare Eye Diseases (WG1)
See more

ERN EYE member investigating site

HCP : Principal investigators

Department of ophthalmology, Kepler University Clinic Linz, Linz, Austria

Adress

Kepler Universitätsklinikum GmbHMed Campus II.Krankenhausstraße 7a

4020 Linz

Austria